Category Archives: Anxiolytics

Overview of New Anxiolytics

Although the benzodiazepines have been the treatment of choice for anxiety disorders for many years, unfavorable aspects to their side-effect profile have initiated efforts to develop new-generation antianxiety agents. Over the past decade, scientists have been searching for compounds that retain the robust anxiolytic efficacy of benzodiazepines, but lack a number of unwanted properties, including… Read More »

Dopaminergic Agents

Sapropterin • The compound patent was filed in 1980 • Launched in 1982 for the treatment of aminoacidopaty by Daiichi Suntory Pharma • Krishnan et al. from the Duke University have recently described a method for treating serotonergic neuro-transmission dysregulation disorders as e.g. anxiety, by administering sapropterin Trifluoperazine hydrochloride • The first patent for trifluoperazine… Read More »

GABAergic Agents

Rilmazafone • The compound patent was filed in 1976 by Shionogi and Co. • Launched in 1989 as sleep-inducing and anxiolytic drug by Shionogi • Kuriyama et al., evaluate the central actions of rilmazafone in terms of its affinity for the benzodiazepine receptor and the activation of GABA receptor binding. It is suggested that the… Read More »

Serotonergic Drugs

Moclobemide • The compound patent was filed in 1976 by Hoffmann-La Roche • Launched in 1990 for the treatment of depression and in 1994 for treat social anxiety by Roche • Unlike other reversible inhibitors of monoamine oxidase, possible side-effects of moclobemide do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia Buspirone… Read More »

Benzodiazepines

Alprazolam • The compound was patented in 1969 by Upjohn Co. • First launched by Pfizer in 1983 for the treatment of anxiety • Approval in the USA for the treatment of panic disorder with or without agoraphobia in 2003 Clonazepam • First described in 1963 as sedative, muscle relaxant and anticonvulsant • Parenteral formulation… Read More »